Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri®) with endogenous IgG4.

Shapiro RI, Plavina T, Schlain BR, Pepinsky RB, Garber EA, Jarpe M, Hochman PS, Wehner NG, Bard F, Motter R, Yednock TA, Taylor FR.

J Pharm Biomed Anal. 2011 Apr 28;55(1):168-75. doi: 10.1016/j.jpba.2011.01.006. Epub 2011 Jan 19.

PMID:
21300512
2.

Quantification and modeling of tripartite CD2-, CD58FC chimera (alefacept)-, and CD16-mediated cell adhesion.

Dustin ML, Starr T, Coombs D, Majeau GR, Meier W, Hochman PS, Douglass A, Vale R, Goldstein B, Whitty A.

J Biol Chem. 2007 Nov 30;282(48):34748-57. Epub 2007 Oct 2.

3.

Attenuated liver fibrosis in the absence of B cells.

Novobrantseva TI, Majeau GR, Amatucci A, Kogan S, Brenner I, Casola S, Shlomchik MJ, Koteliansky V, Hochman PS, Ibraghimov A.

J Clin Invest. 2005 Nov;115(11):3072-82.

4.

Protection against progressive leishmaniasis by IFN-beta.

Mattner J, Wandersee-Steinhäuser A, Pahl A, Röllinghoff M, Majeau GR, Hochman PS, Bogdan C.

J Immunol. 2004 Jun 15;172(12):7574-82.

5.

Expression, purification, and characterization of rat interferon-beta, and preparation of an N-terminally PEGylated form with improved pharmacokinetic parameters.

Arduini RM, Li Z, Rapoza A, Gronke R, Hess DM, Wen D, Miatkowski K, Coots C, Kaffashan A, Viseux N, Delaney J, Domon B, Young CN, Boynton R, Chen LL, Chen L, Betzenhauser M, Miller S, Gill A, Pepinsky RB, Hochman PS, Baker DP.

Protein Expr Purif. 2004 Apr;34(2):229-42.

PMID:
15003256
6.

Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function.

Vora KA, Wang LC, Rao SP, Liu ZY, Majeau GR, Cutler AH, Hochman PS, Scott ML, Kalled SL.

J Immunol. 2003 Jul 15;171(2):547-51.

7.

Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells.

da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu YM, Hochman PS.

J Immunol. 2002 May 1;168(9):4462-71.

9.

Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis.

Runkel L, De Dios C, Karpusas M, Baker D, Li Z, Zafari M, Betzenhauser M, Muldowney C, Miller S, Redlich PN, Grossberg SE, Whitty A, Hochman PS.

J Interferon Cytokine Res. 2001 Nov;21(11):931-41.

PMID:
11747625
10.

Essential role of lymph nodes in contact hypersensitivity revealed in lymphotoxin-alpha-deficient mice.

Rennert PD, Hochman PS, Flavell RA, Chaplin DD, Jayaraman S, Browning JL, Fu YX.

J Exp Med. 2001 Jun 4;193(11):1227-38.

11.

Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity.

Pepinsky RB, LePage DJ, Gill A, Chakraborty A, Vaidyanathan S, Green M, Baker DP, Whalley E, Hochman PS, Martin P.

J Pharmacol Exp Ther. 2001 Jun;297(3):1059-66.

PMID:
11356929
12.

Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity.

Runkel L, deDios C, Karpusas M, Betzenhauser M, Muldowney C, Zafari M, Benjamin CD, Miller S, Hochman PS, Whitty A.

Biochemistry. 2000 Mar 14;39(10):2538-51.

PMID:
10704203
13.

Low affinity binding of an LFA-3/IgG1 fusion protein to CD2+ T cells is independent of cell activation.

Majeau GR, Whitty A, Yim K, Meier W, Hochman PS.

Cell Adhes Commun. 1999;7(3):267-79.

PMID:
10626910
14.

Characterization of a soluble ternary complex formed between human interferon-beta-1a and its receptor chains.

Arduini RM, Strauch KL, Runkel LA, Carlson MM, Hronowski X, Foley SF, Young CN, Cheng W, Hochman PS, Baker DP.

Protein Sci. 1999 Sep;8(9):1867-77.

15.

ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-beta.

Brickelmaier M, Hochman PS, Baciu R, Chao B, Cuervo JH, Whitty A.

J Immunol Methods. 1999 Jul 30;227(1-2):121-35.

PMID:
10485260
16.

Lymph node genesis is induced by signaling through the lymphotoxin beta receptor.

Rennert PD, James D, Mackay F, Browning JL, Hochman PS.

Immunity. 1998 Jul;9(1):71-9.

17.
18.

Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes.

Browning JL, Sizing ID, Lawton P, Bourdon PR, Rennert PD, Majeau GR, Ambrose CM, Hession C, Miatkowski K, Griffiths DA, Ngam-ek A, Meier W, Benjamin CD, Hochman PS.

J Immunol. 1997 Oct 1;159(7):3288-98.

PMID:
9317127
19.

Lymphotoxin but not tumor necrosis factor functions to maintain splenic architecture and humoral responsiveness in adult mice.

Mackay F, Majeau GR, Lawton P, Hochman PS, Browning JL.

Eur J Immunol. 1997 Aug;27(8):2033-42.

PMID:
9295042
20.

Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras.

Sultan P, Schechner JS, McNiff JM, Hochman PS, Hughes CC, Lorber MI, Askenase PW, Pober JS.

Nat Biotechnol. 1997 Aug;15(8):759-62.

PMID:
9255790
21.

Surface lymphotoxin alpha/beta complex is required for the development of peripheral lymphoid organs.

Rennert PD, Browning JL, Mebius R, Mackay F, Hochman PS.

J Exp Med. 1996 Nov 1;184(5):1999-2006.

22.
23.

A novel murine model for the assessment of human CD2-related reagents in vivo.

Ding Y, Qin L, Yang Q, Punch JD, Fox DA, Hochman PS, Bromberg JS.

J Immunol. 1996 Sep 1;157(5):1863-9.

PMID:
8757303
24.

Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival.

Kaplon RJ, Hochman PS, Michler RE, Kwiatkowski PA, Edwards NM, Berger CL, Xu H, Meier W, Wallner BP, Chisholm P, Marboe CC.

Transplantation. 1996 Feb 15;61(3):356-63.

PMID:
8610340
25.

Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers.

Meier W, Gill A, Rogge M, Dabora R, Majeau GR, Oleson FB, Jones WE, Frazier D, Miatkowski K, Hochman PS.

Ther Immunol. 1995 Jun;2(3):159-71.

PMID:
8885134
26.

Proinflammatory responses are efficiently induced by homotrimeric but not heterotrimeric lymphotoxin ligands.

Hochman PS, Majeau GR, Mackay F, Browning JL.

J Inflamm. 1995-1996;46(4):220-34.

PMID:
8878796
27.

Amino acid residues required for binding of lymphocyte function-associated antigen 3 (CD58) to its counter-receptor CD2.

Osborn L, Day ES, Miller GT, Karpusas M, Tizard R, Meuer SC, Hochman PS.

J Exp Med. 1995 Jan 1;181(1):429-34.

28.

The effects of an immunomodulatory LFA3-IgG1 fusion protein on nonhuman primates.

Chisholm PL, Williams CA, Jones WE, Majeau GR, Oleson FB, Burrus-Fischer B, Meier W, Hochman PS.

Ther Immunol. 1994 Aug;1(4):205-16.

PMID:
7584496
30.

Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses.

Miller GT, Hochman PS, Meier W, Tizard R, Bixler SA, Rosa MD, Wallner BP.

J Exp Med. 1993 Jul 1;178(1):211-22.

31.

Molecular analysis of antigen recognition by insulin-specific T-cell hybridomas from B6 wild-type and bm12 mutant mice.

Sherman DH, Hochman PS, Dick R, Tizard R, Ramachandran KL, Flavell RA, Huber BT.

Mol Cell Biol. 1987 May;7(5):1865-72.

32.

A class II gene conversion event defines an antigen-specific Ir gene epitope.

Hochman PS, Huber BT.

J Exp Med. 1984 Dec 1;160(6):1925-30.

33.

B cell activation potential of insulin-reactive T cells in H-2b mice.

Huber BT, Hochman PS.

Eur J Immunol. 1984 Dec;14(12):1106-10.

PMID:
6083870
35.
36.
37.

Carrageenan-induced decline of natural killer activity. I. In vitro activation of adherent non-T-suppressor cells.

Cudkowicz G, Hochman PS.

Cell Immunol. 1980 Aug 1;53(2):395-404. No abstract available.

PMID:
6967769
38.

Suppression of natural cytotoxicity by spleen cells of hydrocortisone-treated mice.

Hochman PS, Cudkowicz G.

J Immunol. 1979 Sep;123(3):968-76. No abstract available.

PMID:
313958
39.

Do natural killer cells engage in regulated reactions against self to ensure homeostasis?

Cudkowicz G, Hochman PS.

Immunol Rev. 1979;44:13-41. Review.

PMID:
367948
40.

Decline of natural killer cell activity in sublethally irradiated mice.

Hochman PS, Cudkowicz G, Dausset J.

J Natl Cancer Inst. 1978 Jul;61(1):265-8.

PMID:
276634
41.
42.

Evidence for a similar or common mechanism for natural killer cell activity and resistance to hemopoietic grafts.

Kiessling R, Hochman PS, Haller O, Shearer GM, Wigzell H, Cudkowicz G.

Eur J Immunol. 1977 Sep;7(9):655-63. No abstract available.

PMID:
336380

Supplemental Content

Loading ...
Support Center